بدوى عبد الخالق عبد العزيز عمر
أستاذ
Novel predictors of early atherosclerosis in nonalcoholic fatty liver disease
Clin Exp HEPATOL • 2023
معلومات البحث
المؤلفون
Badawy Abdulkhalik Abdulaziz1
, Ahmed Mahmoud Bendary2
, Aida Thabet3
, Eman Gamal Behery3
, Mona Salah1
,
Medhat A Khalil4
, Ghadeer Rashad1
الكلمات المفتاحية
metabolic associated fatty liver disease, cardiovascular disease, carotid intimal media thickness,
endocan, mean platelet volume.
المجلة العلمية
Clin Exp HEPATOL
الناشر
clinical and experimental hepatology
المجلد
9
العدد
2
الصفحات
1-9
publication.type
International
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Aim of the study: Non-alcoholic fatty liver disease (NAFLD) is regarded as the most relevant liver disease of
the twenty-first century, affecting at least one third of the general population. NAFLD is associated with increased
mortality due to cardiovascular disease (CVD) and cancer. The carotid intimal media thickness (CIMT), mean platelet volume (MPV) and endocan level could be markers for generalised atherosclerotic burden and endothelial
dysfunction. The aims of the study were to evaluate the association between non-alcoholic fatty liver disease
and early atherosclerosis by measuring CIMT, MPV and endocan level, as markers of endothelial dysfunction,
in NAFLD patients.
Material and methods: This cross-sectional study included 50 patients who were divided into two groups:
group I included 25 subjects with NAFLD and group II included 25 healthy subjects. Complete blood count with
MPV, liver profile, lipid profile, fasting blood glucose level, 2-hour postprandial kidney function test, and serum
concentrations of endocan were measured for all patients. NAFLD fibrosis score (NFS) was calculated. Abdominal
ultrasonography and carotid ultrasound scan for measurement of CIMT were performed.
Results: Serum endocan levels, MPV and CIMT were significantly higher (p < 0.005) in NAFLD patients (0.6,
9.3 ±1.2 and 0.9 ±0.3 respectively) than healthy subjects (0.1, 8.1 ±0.6 and 0.6 ±0.1 respectively). The analysis
of diagnostic performance of these factors revealed that they have good sensitivity and specificity in prediction
of endothelial dysfunction with AUC (0.950, 0.844 and 0.849 respectively).
Conclusions: Serum endocan levels, MPV and CIMT could be considered as good predictors of endothelial dysfunction and therefore early detection of subclinical atherosclerosis in NAFLD patients.
the twenty-first century, affecting at least one third of the general population. NAFLD is associated with increased
mortality due to cardiovascular disease (CVD) and cancer. The carotid intimal media thickness (CIMT), mean platelet volume (MPV) and endocan level could be markers for generalised atherosclerotic burden and endothelial
dysfunction. The aims of the study were to evaluate the association between non-alcoholic fatty liver disease
and early atherosclerosis by measuring CIMT, MPV and endocan level, as markers of endothelial dysfunction,
in NAFLD patients.
Material and methods: This cross-sectional study included 50 patients who were divided into two groups:
group I included 25 subjects with NAFLD and group II included 25 healthy subjects. Complete blood count with
MPV, liver profile, lipid profile, fasting blood glucose level, 2-hour postprandial kidney function test, and serum
concentrations of endocan were measured for all patients. NAFLD fibrosis score (NFS) was calculated. Abdominal
ultrasonography and carotid ultrasound scan for measurement of CIMT were performed.
Results: Serum endocan levels, MPV and CIMT were significantly higher (p < 0.005) in NAFLD patients (0.6,
9.3 ±1.2 and 0.9 ±0.3 respectively) than healthy subjects (0.1, 8.1 ±0.6 and 0.6 ±0.1 respectively). The analysis
of diagnostic performance of these factors revealed that they have good sensitivity and specificity in prediction
of endothelial dysfunction with AUC (0.950, 0.844 and 0.849 respectively).
Conclusions: Serum endocan levels, MPV and CIMT could be considered as good predictors of endothelial dysfunction and therefore early detection of subclinical atherosclerosis in NAFLD patients.
